Ineke Tieken

Dr. Ineke Tieken

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Transplantation
Verified
Journal Article
Open access
DZDaniel Zecher
Daniel Zecher
FZFlorian Zeman
Florian Zeman
TDThomas Drasch
Thomas Drasch
ITIneke Tieken
Ineke Tieken
SHSebastiaan Heidt
Sebastiaan Heidt
Bernhard BanasBernhard Banas
Bernhard Banas
Export Background. Assignment of unacceptable HLA mismatches (UAMs) prevents transplantation of incompatible grafts but potentially prolongs waiting time. Whether this is true in the Eurotransplant Kidney Allocation System (ETKAS) and the Eurotransplant Senior Program in Germany is highly debated and relevant for UAM policies. Methods Donor pool restriction due to UAM was expressed as percent virtual panel-reactive antibodies (vPRAs). Kaplan-Meier estimates and multivariable Cox regression models were used to analyze the impact of vPRA levels on waiting time and transplant probability during a period of 2 years in all patients eligible for a kidney graft unter standard circumstances in Germany on February 1, 2019 (n = 6533). Utility of the mismatch probability score to compensate for sensitization in ETKAS was also investigated. Results In ETKAS, donor pool restriction resulted in significant prolongation of waiting time and reduction in transplant probability only in patients with vPRA levels above 85%. This was most evident in patients with vPRA levels above 95%, whereas patients in the acceptable mismatch program had significantly shorter waiting times and higher chances for transplantation than nonsensitized patients. In the Eurotransplant Senior Program, vPRA levels above 50% resulted in significantly longer waiting times and markedly reduced the chance for transplantation. Compensation for sensitization by the mismatch probability score was insufficient. Conclusions Donor pool restriction had no significant impact on waiting time in most sensitized patients. However, despite the existence of the acceptable mismatch program, the majority of highly sensitized patients is currently disadvantaged and would benefit from better compensation mechanisms.

29 November 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
FCFerran Coens
Ferran Coens
NKNoël Knops
Noël Knops
ITIneke Tieken
Ineke Tieken
SVSerge Vogelaar
Serge Vogelaar
ABAndreas Bender
Andreas Bender
CRCertain Registry
Certain Registry
Background: Little is known about the time-varying determinants of kidney graft failure in children. Methods: We performed a retrospective study of primary pediatric kidney transplant recipients (younger than 18 years) from the Eurotransplant registry (1990–2020). Piece-wise exponential additive mixed models were applied to analyze time-varying recipient, donor, and transplant risk factors. Primary outcome was death-censored graft failure. Results: We report on 4528 kidney transplantations, of which 68% with deceased and 32% with living donor. One thousand six hundred and thirty-eight recipients experienced graft failure, and 168 died with a functioning graft. Between 2011 and 2020, the 5-year graft failure risk was 10% for deceased donor and 4% for living donor kidney transplant recipients. Risk of graft failure decreased five-fold from 1990 to 2020. The association between living donor transplantation and the lower risk of graft failure was strongest in the first month post-transplant (adjusted hazard ratio, 0.58; 95% confidence interval, 0.46 to 0.73) and remained statistically significant until 12 years post-transplant. Risk factors for graft failure in the first 2 years were deceased donor younger than 12 years or older than 46 years, potentially recurrent kidney disease, and panel-reactive antibody >0%. Other determinants of graft failure included dialysis before transplantation (until 5 years post-transplant), human leukocyte antigen mismatch 2–4 (0–15 years post-transplant), human leukocyte antigen mismatch 5–6 (2–12 years post-transplant), and hemodialysis (8–14 years post-transplant). Recipients older than 11 years at transplantation had a higher risk of graft failure 1–8 years post-transplant compared with other age groups, whereas young recipients had a lower risk throughout follow-up. Analysis of the combined effect of post-transplant time and recipient age showed a higher rate of graft failure during the first 5 years post-transplant in adolescents compared with young transplant recipients. In contrast to deceased donor younger than 12 years, deceased donor older than 46 years was consistently associated with a higher graft failure risk. Conclusions: We report a long-term inverse association between living donor kidney transplantation and the risk of graft failure. The determinants of graft failure varied with time. There was a significant cumulative effect of adolescence and time post-transplant. The ideal donor age window was dependent on time post-transplant.

4 October 2021 in Transplantation
Verified
Journal Article
Open access
VAVolker Assfalg
Volker Assfalg
GMGregor Msc Miller
Gregor Msc Miller
FSFelix Stocker
Felix Stocker
MMMarieke van Meel
Marieke van Meel
TGTiny Groenevelt
Tiny Groenevelt
UHUwe Heemann
Uwe Heemann
Background.: At Eurotransplant (ET), kidneys are transferred to “rescue allocation” (RA), whenever the standard allocation (SA) algorithms Eurotransplant Kidney Allocation System (ETKAS) and Eurotransplant Senior Program (ESP) fail. We analyzed the outcome of RA. Methods.: Retrospective patient clinical and demographic characteristics association analyses were performed with graft outcomes for 2422 recipients of a deceased donor renal transplantation (DDRT) after RA versus 25 481 after SA from 71 centers across all ET countries from 2006 to 2018. Results.: Numbers of DDRTs after RA increased over the time, especially in Germany. RA played a minor role in ESP versus ETKAS (2.7% versus 10.4%). RA recipients and donors were older compared with SA recipients and donors, cold ischemia times were longer, waiting times were shorter, and the incidence of primary nonfunction was comparable. Among ETKAS recipients, HLA matching was more favorable in SA (mean 3.7 versus 2.5). In multivariate modeling, the incidence of graft loss in ETKAS recipients was reduced in RA compared with SA (subdistribution hazard ratio, 0.80; 95% confidence interval [0.70-0.91], P < 0.001), whereas other outcomes (mortality, death with functioning graft (DwFG)) were not significantly different. None of the 3 outcomes were significantly different when comparing RA with SA within the ESP program. Conclusions.: Facing increased waiting times and mortality on dialysis due to donor shortage, this study reveals encouragingly positive DDRT outcomes following RA. This supports the extension of RA to more patients and as an alternative tool to enable transplantation in patients in countries with prohibitively long waiting times or at risk of deterioration.

3 April 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
WMWouter T. Moest
Wouter T. Moest
AMA. Lianne Messchendorp
A. Lianne Messchendorp
HDHelma Dolmans
Helma Dolmans
CKCynthia Konijn-Janssen
Cynthia Konijn-Janssen
SEStan van Den Eijnden
Stan van Den Eijnden
JRJoris I. Rotmans
Joris I. Rotmans
Background: BK polyomavirus (BKPyV) infection is of notable concern in kidney transplant recipients, as it can cause BKPyV-associated nephropathy (BKPyVAN). Currently, there is no effective treatment for BKPyV infection, underscoring the need for preventive strategies. There is emerging evidence that donor-derived BKPyV plays a role in the development of BKPyV DNAemia. To further explore this hypothesis, we conducted a retrospective, multi-center cohort study to evaluate the risk of developing BKPyV DNAemia in kidney recipient pairs sharing the same donor. Methods: At the Leiden University Medical Center (LUMC), deceased donor kidney transplant recipients (2011–2021) were identified and classified according to the occurrence of BKPyV DNAemia within the first year post-transplantation. For each recipient, the contralateral kidney recipient from the same donor was identified through national transplant registries. Cox regression was used to assess whether BKPyV DNAemia in the LUMC recipient was associated with an increased risk of BKPyV DNAemia in the contralateral recipient. Results: Among 117 recipient pairs, BKPyV DNAemia was more frequent when the contralateral recipient was affected (28.8% [15/52]), compared with pairs in which the contralateral recipient remained unaffected (10.8% [7/65], p = 0.013). Multivariable Cox regression analysis confirmed this increased risk (HR 4.9, 95% CI: 1.8–13.6; p = 0.002). Conclusions: This study shows a significantly increased risk of BKPyV DNAemia in recipients of deceased donor kidneys when the contralateral kidney recipient develops BKPyV DNAemia. These findings highlight the influence of donor-derived factors in BKPyV transmission in kidney transplantation.

3 October 2025 in Nephrologie Aktuell
Verified
Journal Article
Closed access
PDF file
ITIneke Tieken
Ineke Tieken
MBMilou van Bruchem
Milou van Bruchem
VAVolker Aßfalg
Volker Aßfalg
Zusammenfassung: Die Organvergabe, Allokation, erfolgt in Deutschland durch die Internationale Eurotransplant Stiftung mit Sitz im niederländischen Leiden zusammen mit 7 weiteren mitteleuropäischen Ländern. Die Vergabe muss sich hierbei an medizinisch gesicherte Erkenntnisse halten, damit die Transplantationsergebnisse optimiert werden. Darüber hinaus sind jedoch auch ethische Gesichtspunkte zu berücksichtigen und organspezifische Besonderheiten in den Allokationsprozess einzubinden. Die Allokation jedes Organs folgt dabei klar definierten Regeln. Darüber hinaus hat Eurotransplant besondere Regeln für die Vergabe von Organen entwickelt, die von älteren Spendern stammen oder abgelehnt wurden oder aufgrund von medizinischen oder logistischen Begleitumständen nicht direkt vermittelt werden können. Das Ziel der Organallokation ist es, möglichst alle transplantablen Organe rasch und mit anschließend gutem Transplantationsergebnis zu vermitteln.

12 November 2026 in Health Care Management Science
Verified
Journal Article
Closed access
PDF file
HFH.C. de Ferrante
H.C. de Ferrante
RGR. Laguna Goya
R. Laguna Goya
BSB.M.L. Smeulders
B.M.L. Smeulders
FSFrits Spieksma
Frits Spieksma
ITIneke Tieken
Ineke Tieken